Pharming Group PHARM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHARM is a good fit for your portfolio.
News
-
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
-
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
-
Pharming Group to participate in April investor conferences
-
Pharming Group reports fourth quarter and full year 2023 financial results
-
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
-
Pharming Group to participate in February investor conferences
-
First Citizens' stock leaps on SVB deal, Carnival share drop after downbeat outlook, and other stocks on the move
Trading Information
- Previous Close Price
- €0.91
- Day Range
- €0.89–0.92
- 52-Week Range
- €0.86–1.31
- Bid/Ask
- €0.90 / €0.91
- Market Cap
- €609.12 Mil
- Volume/Avg
- 6.5 Mil / 6.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 382
- Website
- https://www.pharming.com
Comparables
Valuation
|
Metric
|
PHARM
|
NAMS
|
PHVS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.94 | 5.79 | 2.57 |
Price/Sales | 2.78 | 117.97 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PHARM
NAMS
PHVS
Financial Strength
|
Metric
|
PHARM
|
NAMS
|
PHVS
|
|---|---|---|---|
Quick Ratio | 3.28 | 6.86 | 9.85 |
Current Ratio | 4.06 | 6.95 | 10.46 |
Interest Coverage | −1.63 | — | — |
Quick Ratio
PHARM
NAMS
PHVS
Profitability
|
Metric
|
PHARM
|
NAMS
|
PHVS
|
|---|---|---|---|
Return on Assets (Normalized) | −3.53% | −34.73% | −50.56% |
Return on Equity (Normalized) | −7.44% | −39.45% | −56.14% |
Return on Invested Capital (Normalized) | −3.56% | −41.57% | −56.14% |
Return on Assets
PHARM
NAMS
PHVS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gsbdlfjsz | Qgdg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Crqphlrv | Xnrrx | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zyqxvlks | Zttwbd | $99.6 Bil | |
MRNA
| Moderna Inc | Wvlhvkfc | Dmqj | $38.8 Bil | |
ARGX
| argenx SE ADR | Kczxhmltr | Jfz | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Xcvthrtbv | Bmc | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cpbrqrt | Vsbhtq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lvjsgysn | Vgsvr | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mbspqdsjd | Hcvrcp | $12.4 Bil | |
INCY
| Incyte Corp | Pgzctyvb | Kmbcvq | $11.9 Bil |